Last reviewed · How we verify
VEC
VEC is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
VEC is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Colorectal cancer (advanced or metastatic).
At a glance
| Generic name | VEC |
|---|---|
| Also known as | Vincristine, Etoposide, Cyclophosphamide |
| Sponsor | Centre Leon Berard |
| Drug class | Therapeutic cancer vaccine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
VEC (developed by Centre Leon Berard) is designed to activate T-cell mediated immunity against cancer by presenting tumor antigens to the immune system. As a marketed therapeutic vaccine, it works by priming the body's adaptive immune response to target malignant cells, potentially used in combination with other immunotherapies or as monotherapy depending on the indication.
Approved indications
- Colorectal cancer (advanced or metastatic)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Flu-like symptoms
Key clinical trials
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (PHASE2)
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (PHASE2)
- Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa (PHASE1, PHASE2)
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (PHASE3)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 (PHASE1)
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
- Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |